Trial Profile
Human Laboratory Study of ANS-6637 for Alcohol Use Disorder
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Mar 2022
Price :
$35
*
At a glance
- Drugs ANS 6637 (Primary)
- Indications Alcoholism
- Focus Proof of concept; Therapeutic Use
- 31 Aug 2020 Status changed from suspended to discontinued.
- 01 Jun 2020 Status changed from active, no longer recruiting to suspended.
- 18 Nov 2019 According to an Amygdala Neurosciences media release, the company has secured $5.6M financing which will be used to fund this trial.